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Background
Diabetes mellitus (DM) is now prevalent in many countries in sub-
Saharan Africa, with associated health and socioeconomic consequences. 
Adherence to antidiabetic medications has been shown to improve 
glycaemic control, which subsequently improves both the short- and long-
term prognosis of  the disease. The main objective of  this study was to 
assess the level of  adherence to antidiabetic drugs among outpatients in a 
teaching hospital in southwestern Nigeria. 
Methods
A cross-sectional study was carried out using the eight-item Morisky 
Medication Adherence Scale (MMAS-8) among diabetic patients attending 
the medical outpatients’ diabetes clinic of  Ladoke Akintola University 
Teaching Hospital, in Ogbomosho, Oyo State in southwestern Nigeria, 
during a three-month period (October to December 2013).
Results
A total of  129 patients participated in the study with a male-to-female ratio 
of  1:1.5. Seventy-eight (60.5%) patients had systemic hypertension as a 
comorbid condition while the remaining were being managed for diabetes 
mellitus alone. Only 6 (4.7%) of  the patients had type 1 DM while the 
remaining 123 (95.3%) were diagnosed with type 2 DM. Metformin was 
the most prescribed oral hypoglycaemic agent (n = 111, 58.7%)  followed 
by glibenclamide (n = 49, 25.9%). Medication adherence was classified 
as good, medium, and poor for 52 (40.6%), 42 (32.8%), and 34 (26.6%) 
patients, respectively.
Medication costs accounted for 72.3% of  the total direct cost of  DM in 
this study, followed by the cost of  laboratory investigations (17.6%).
Conclusion
Adherence of  diabetes patients in the study sample to their medications 
was satisfactory. There is a need for the integration of  generic medicines 
into routine care as a way of  further reducing the burden of  healthcare 
expenditure on the patients. 
Introduction
Diabetes mellitus (DM) is now one of  the most common 
non-communicable diseases affecting the global population, 
with increasing incidence in many emerging countries of  the 
world1-3. In developing countries like Nigeria, the incidence 
of  DM, especially the type 2 variant, is on the increase, with 
its attendant complications. According to the International 
Diabetic Federation (IDF), the prevalence of  DM will 
increase by as much as 54% globally between 2010 and 
2030 with projections for countries in sub-Saharan Africa 
close to 100%4. In Nigeria, studies from different parts of  
the country have recorded prevalence rates between 1% and 
8%5-8.
The management of  DM consists of  lifestyle and dietary 
changes and pharmacotherapy. For patients with type 1 DM, 
insulin remains the mainstay of  treatment while the different 
groups of  oral hypoglycaemic agents (OHA) and insulin are 
used in treating patients with type 2 DM. Studies have shown 
that adequate glycaemic control will slow down or prevent 
the development of  microvascular and macrovascular 
complications of  both types of  DM9-12. Adherence to anti-
diabetic medications has been shown to improve glycaemic 
control, which augurs well for the long-term prognosis 
of  the disease13,14. Medication adherence to antidiabetic 
agents has also been shown to be more cost-effective, as it 
may reduce hospitalization frequency and costs associated 
with both short- and long-trem complications15,16. Some 
of  the reasons or predictors of  poor adherence found in 
the literature include high pill burden, complexity of  drug 
regimens forgetfulness, high cost of  medications, presence 
or perceived fear of  adverse effects, and poor knowledge 
about the disease condition17-19.
Worldwide, studies on medication adherence among diabetes 
patients have shown a wide variation. Ahmad et al. reported 
53% non-adherence among diabetics in Malaysia; similar 
studies in India and Ethiopia have reported non-adherence 
rates of  42.3% and 25.4%, respectively19-21. Recent Nigerian 
studies using different instruments revealed non-adherence 
rates between 27.5% and 50%22-24. These Nigerian studies 
investigated medication adherence among diabetes 
patients and its association with the number of  prescribed 
medications and glycaemic control. The relationship between 
cost of  medications and adherence is well established in the 
literature15,25. The issue of  cost of  medications and indeed 
healthcare expenditure is especially germane in developing 
countries like Nigeria, where the majority of  patients pay out 
of  pocket26. The national health insurance scheme (NHIS), 
which has been operational for about a decade now, covers 
less than 10% of  the country’s population: mainly those in 
the formal sectors of  the economy27, 28.
The principal objective of  the study was to assess the level 
of  adherence to OHAs and insulin among diabetes patients 
attending the medical outpatient clinics of  a tertiary hospital 
in Nigeria. Secondary objectives included: the prescription 
pattern for OHAs, some components of  direct costs, and 
the effects of  various factors on medication costs.
Methods
Study setting
The study was carried out in the medical outpatients’ diabetes 
clinic of  a tertiary-level healthcare facility in Nigeria during a 
three-month period (October to December 2013). The study 
centre was Ladoke Akintola University Teaching Hospital 
in Ogbomosho, Oyo State in southwestern Nigeria. This 
site caters for the population of  Oyo and its surrounding 
states. This teaching hospital is the major referral hospital 
in the northern part of  Oyo State and draws its patient 
population from numerous private hospitals and primary 
and secondary healthcare facilities in the region. The medical 
outpatients’ clinic is manned by a consultant endocrinologist 
physician, registrars (senior and junior) in internal medicine, 
and medical interns. The centre runs a weekly clinic with an 
average attendance between 30 and 60 patients.
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Study population
Consecutive patients who had been diagnosed with type 1 
and type 2 DM and who had been on treatment in the study 
centre were invited to participate in the study. Patients older 
than 18 years of  age, who had been on medication for at 
least six months, and gave informed consent were included 
in the study. Patients younger than 18 years, those who 
refused to consent, and those with acute symptomatology 
were excluded from the study. All participating patients were 
paying out of  pocket, as they were not enrolled under the 
national health insurance scheme of  the country.
Sampling
Sample size
The number of  patients needed for this study was calculated 
using the formula for descriptive studies:
Sample size (n) = [DEFF*Np(1-p)]/ [(d2/Z21-α/2*(N-
1)+p*(1-p)] 
Where, N = Population size (600) 
 p =  prevalence of  poor adherence (0.4) 
 d = Precision (0.1) 
 DEFF = Design effect (1.5) 
 Z1-α/2 = 1.96 
The estimated prevalence of  poor adherence of  40% 
was chosen based on results from two similar Nigerian 
studies with values of  27.5% and 50% respectively22, 24. An 
estimated minimum sample size of  129 was obtained using 
the aforementioned assumptions. A convenience sampling 
method was used, as consecutive patients presenting at the 
clinic were recruited.
Study Instrument
A cross-sectional study was done using a validated self-
reported adherence tool (the eight-item Morisky Medication 
Adherence Scale (MMAS-8))29. The MMAS-8, a validated 
instrument with high reliability and validity, has been used 
for studies on medication adherence among diabetes patients 
in many countries19,30,31. In Nigeria, the MMAS has been used 
for studies on medication adherence among hypertensive 
and psychiatric patients32,33. A previous Nigerian study on 
medication adherence among diabetes patients used the 
modified MMAS-4 instrument34. It collects information on 
how frequently patients may forget to take their medications 
and the reasons for this using a binary (Yes/No) and a five-
option response version (never/rarely/sometimes/often/
always). The summary of  the scoring interpretation is as 
follows: 0 (for high adherence), 1-2 (medium adherence) 
and > 2 (poor adherence). An additional questionnaire for 
collection of  sociodemographic details, diagnoses, a list 
of  prescribed medications, some components of  direct 
costs (cost of  medications, laboratory investigations, 
transportation to and from hospital, and consultation) and 
factors that may affect adherence was also administered. 
The additional questionnaire, a mixture of  open- and 
closed-ended statements was developed by the authors 
for the purpose of  this study and was pre-tested among 
ten diabetes patients who were attending another tertiary 
healthcare facility in Ekiti State, southwestern Nigeria. 
Necessary adjustments were made in the contents and 
structure before its administration. The questionnaires were 
administered by medical interns during clinic encounters 
after informed consent was obtained. Glycaemic control was 
assessed using the average of  the two most recent fasting 
plasma glucose and/or glycosylated haemoglobin (HbA1c) 
measurements available. The blood glucose was done with 
capillary blood taken from the patients’ finger and analyzed 
using a glucometer in the clinic early in the morning before 
consultation starts. The investigators ensured that there was 
no discrimination against those that refused participation in 
the study by attending to them promptly and professionally. 
Six months of  medication use was chosen as the cut-off  
for inclusion into the study because most patients had 
appointments either monthly or every other month and 
would have had between three and six clinic appointments 
by the time they were recruited into the study. The monthly 
cost of  the prescribed medications was calculated using the 
price list of  the hospital pharmacy, while patients gave an 
estimate of  their individual transport fares to and from the 
hospital. The consultation fee is a constant one charged by 
the hospital for a consulting encounter with a physician. 
Written consent was obtained from each patient during study 
recruiment. Ethical approval was obtained from the Research 
Ethics Committee of  the hospital before commencement of  
the study.
Statistical Analysis
The information obtained from the general questionnaire 
was coded and entered using IBM SPSS version 19 (IBM 
Corporation, Armonk, NY, USA). The information from 
the MMAS-8 was interpreted using its keys and entered. 
General characteristics of  the patients were analyzed using 
descriptive statistics. Demographic variables that were 
normally distributed were described by mean and standard 
deviation. The median and range were calculated for other 
demographic variables that were not normally distributed. 
Categorical variables are reported as frequency distributions 
and proportions with 95% confidence intervals and were 
compared using the chi-square test or Fisher’s exact 
test. Comparisons of  the means of  some variables (age, 
fasting plasma glucose, HbA1c, monthly income, monthly 
medication cost) were done using analysis of  variance 
(ANOVA) with a p-value of  < 0.05 taken as the level of  
statistical significance. 
Results
A total of  129 patients participated in the study with a male-
to-female ratio of  1:1.5. The sociodemographic variables 
of  the participants are shown in Table 1. Seventy-eight 
patients (60.5%) had systemic hypertension as a comorbid 
condition, while the remaining were being managed for 
DM alone.  Only six (4.7%) of  the patients had type 1 DM, 
while the remaining 123 (95.3%) were diagnosed with type 
2 DM. The median duration of  disease (time since initial 
diagnosis was made) was seven years, while the median 
duration of  clinic attendance was three years. The average 
of  the previous two fasting plasma glucose measurements 
(done on the morning of  clinic appointments) of  the 
patients was 8.2 ± 3.4 mmol/L while the mean HbA1c 
(done within the previous three months) was 7.5 ± 2.4%. 
On further analysis, only 45.9% (n = 50) of  the patients had 
their fasting plasma glucose within the normal range (4 to 
6.9 mmol/L), while 50% of  those who had HbA1c done in 
the previous three months recorded values within normal 
range. Five hundred five medications were prescribed for 
the patients, with a mean number of  4.1 ± 1.4 prescribed 
per patient. The frequency distribution of  number of  
prescribed drugs is shown in Figure 1. The breakdown of  
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the drugs is as follows: 220 antidiabetic agents prescribed 
(43.6%), 163 antihypertensives (32.3%), 23 antilipemics 
(4.5%), and 42 anti-platelets (8.3%). Insulin usage either 
alone or in combination with oral hypoglycaemic agents was 
observed in 14.1% of  patients, while the majority of  patients 
(85.9%) had OHAs alone as antidiabetic agents. Metformin, 
with 111 prescriptions (58.7%), was the most prescribed 
oral hypoglycaemic agent followed by glibenclamide 
(49 prescriptions, 25.9%). Glimepiride, vildagliptin and 
pioglitazone were prescribed for 26 (13.8%), 2 (1.1%) and 
1 (0.5%) of  the patients respectively. Combination therapy 
of  oral hypoglycaemic agents was prescribed in 74 (57.4%), 
oral hypoglycaemic agents and insulin in 18 (14%) and 
metformin alone 15 (11.6%). Lisinopril (37.4%) was the 
most prescribed antihypertensive, followed by nifedipine 
(16.6%) and hydrochlorothiazide (14.1%). The groups of  
prescribed antihypertensives are shown in Figure 2.
Medication adherence among the patients was grouped 
as follows: 52 good (40.3%), 43 medium (33.3%), and 34 
poor (26.4%). The mean monthly cost of  medications was 
N6557 ± N4463 Nigerian Naira (NGN) while the median 
monthly amount spent on transportation, investigations and 
consultations was NGN N400, N800 and N250, respectively 
(165 Nigerian Naira = 1 US Dollar, USD, at the time of  data 
collection). The total amount (direct cost) expended monthly 
by patients was NGN N1,096,668, of  which medications, 
laboratory investigations, transportation and consultation 
fees accounted for 72.3%, 17.6%, 7% and 3.1%, respectively. 
The descriptive statistics of  the means of  the different 
components of  direct cost is shown in Table 4.
The relationship between medication adherence, sex, level 
of  education, monthly income and other categories was 
explored using the chi-square.test (Table 2). The variation 
of  the mean HbA1c levels among the three adherence 
groups was statistically  significant (p = 0.003). Details of  
the comparison are shown in Table 3. The relationship 
between average duration of  illness and the three adherence 
groups is shown in Figure 3, and Figure 4 depicts the the 
mean HbA1c levels of  the three groups. The most common 
factors, according to the study participants, that may affect 
adherence to medications were cost of  treatment (20.2%), 
lack of  family support (11%), high pill burden (11%), 
cultural and religious beliefs (10%), inadequate information 
about therapy (10%) and non-availability of  prescribed 
medications (10%).



















Number of prescribed drugs
Figure 2. Percentages of prescribed antihypertensives by drug class at LAUTECH Teaching Hospital 
diabetes clinic
ARB = Angiotensin Receptor Blocker
ACI = Angiotensin-Converting Enzyme Inhibitor














Figure 3. Relationship between duration of DM and the three levels of adherence at LAUTECH Teaching 
Hospital diabetes clinic
Duration of Illness = time since first diagnoses of diabetes mellitus (DM) was made
Adherence groups were defined based on the level of diabetes patient adherence to medications according to the 
Morisky Medication Adherence Scale (MMAS-8) questionnaire results
 
Adherence Group 
Figure 4. Relationship between mean HbA1c and three levels of adherence at LAUTECH Teaching 
Hospital diabetes clinic
HbA1c = blood glycosylated haemoglobin concentration
Adherence groups were defined based on the level of diabetes patient adherence to medications according to the 
Morisky Medication Adherence Scale (MMAS-8) questionnaire results
 
Adherence Group 
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Discussion
The results above have described, in detail, the prescribing 
pattern of  antidiabetic drugs, some direct costs, and 
adherence of  patients to treatment. Female patients made up 
the larger proportion of  patients in our study; this reflects the 
general trend from similar studies among diabetes patients 
worldwide35-37. The mean age of  61.4 ± 10.5 years found in 
this study is close to the 58.15 ± 9 .16 years and 61 ± 12.3 
years recorded in work from Malaysia and the USA31,38.
Achieving and keeping good glycaemic control (fasting 
plasma glucose < 110mg/dl or 6.1 mmol/L) is the goal of  
pharmacotherapy among diabetes patients, though this is not 
possible in a large percentage of  them. Less than 50% of  
the study participants had good glycaemic control, similar to 
the 40.3% in another Nigerian study34. Studies conducted in 
Ethiopia and Nepal found glycaemic control rates of  41.8% 
and 49.5% respectively39,40. Of  the 16 patients (12.4%) who 
were able to obtain (afford) HbA1c as a biomarker for 
glycaemic control, 50% of  them had their values within 
normal limits. The mean plot for HbA1c (Figure 3) reveals 
a trend of  higher values of  
HbA1c in poorly adherent 
patients. This supports 
the statistical significant 
difference found when the 
average HbA1c was compared 
between the three adherence 
groups. Though HbA1c was 
tested in a small number of  
patients (because of  financial 
constraints), this trend shows 
the importance of  HbA1c as 
a useful tool for monitoring 
medication adherence among 
diabetes patients.
The number of  drugs 
prescribed for patients 
has been found to affect 
adherence to treatment. The 
Table 1. Sociodemographic data of study participants attending diabetes clinic at LAUTECH Teaching Hospital





No Education 22 17.6
Primary Education 30 24
Secondary Education 20 16





< 30yrs 2 1.6
31 – 44yrs 5 4.1
45 – 64yrs 61 49.6
> 65yrs 55 44.7
MONTHLY INCOME
< 20,000 Naira 50 43.1
20 – 50,000 Naira 37 31.9
50 – 100,000 Naira 22 19
> 100,000 Naira 7 6
₦165 Nigerian Naira = $1 US Dollar at the time of data collection
Table 2. Associations between study participant drug adherence and other variables at LAUTECH 
Teaching Hospital diabetes clinic
Adherence level X2 df p-value
Monthly Income 5.25 2 0..51
Sex 3.39 2 0.18
Level of Education 6.2 6 0.40
Age group 5.06 6 0.54






X2 = chi-square statistic
df = degrees of freedom
HbA1c = blood glycosylated haemoglobin concentration
 
Table 3. Comparison of means of some variables between the three levels of adherence among study patients at 
LAUTECH Teaching Hospital
Sum of Squares df Mean Square F p-value
HbA1c Between Groups 50.519 2 25.260 9.049 .003
Within Groups 36.290 13 2.792
Total 86.809 15
Mean number of drugs Between Groups 2.846 2 1.423 .785 .458




Between Groups 10.580 2 5.290 .486 .616
Within Groups 1109.207 102 10.875
Total 1119.787 104
Cost of medications Between Groups 1.784E7 2 8922409.439 .445 .642
Within Groups 2.347E9 117 2.006E7
Total 2.365E9 119
Duration of illness Between Groups 12.259 2 6.130 .161 .851
Within Groups 4061.705 107 37.960
Total 4073.964 109
Monthly income Between Groups .798 2 .399 .462 .631
Within Groups 96.733 112 .864
Total 97.530 114
AGE Between Groups 377.306 2 188.653 1.741 .180
Within Groups 12893.317 119 108.347
Total 13270.623 121
HbA1c = blood glycosylated haemoglobin concentration
df = degrees of freedom
F = F-ratio
 
Table 4. Descriptive statistics of components of direct costs for study participants at LAUTECH Teaching Hospital diabetes clinic
n Mean Std. Deviation Median
95% Confidence Interval for Mean
Minimum Maximum p-valueLower Bound Upper Bound
Monthly medication cost Good 49 6772.45 4804.102 5000 5392.55 8152.35 1000 20000 .64
Moderate 39 6900.00 4140.303 5557.87 8242.13 1300 20000
Poor 32 5965.62 4353.390 4396.06 7535.19 1000 16500
Total 120 6598.75 4457.614 5793.00 7404.50 1000 20000
Monthly cost of 
investigations
Good 44 1498.64 1891.121 800 923.68 2073.59 200 10000 .81
Moderate 38 1772.89 2603.174 917.25 2628.54 150 10000
Poor 32 1807.81 2633.595 858.30 2757.32 200 11000
Total 114 1676.84 2345.813 1241.57 2112.12 150 11000
Monthly transportation cost Good 48 609.79 709.232 400 403.85 815.73 60 3000 .92
Moderate 42 641.19 869.853 370.13 912.26 10 4000
Poor 30 682.33 663.105 434.73 929.94 60 3000
Total 120 638.92 753.217 502.77 775.07 10 4000
Consultation fees Good 34 223.53 105.339 250 186.77 260.28 100 500 .24
Moderate 37 400.09 498.259 233.96 566.21 3 3000
Poor 26 404.05 737.844 106.03 702.07 5 4000
Total 97 339.26 495.978 239.30 439.22 3 4000
Prices in Nigerian Naira, ₦ (₦165 Nigerian Naira = $1 US Dollar at the time of data collection)
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average number of  prescribed medications in this study was 
4.1 ± 1.4; this is close to the 4.6 found in another Nigerian 
study and less than the 5.56 ± 2.52 in an Indian study24,41. 
Oral hypoglycaemic agents were the most prescribed drugs 
in our study, with metformin either alone or in combination 
with other hypoglycaemic agents. Yusuff  et al. found that oral 
hypoglycaemic agents were prescribed in 86% of  cases while 
a similar study involving 384 type 2 diabetes patients had 
over 91% of  these patients prescribed oral hypoglycaemic 
drugs23,40. Oral agents from the thiazolidinedione and DPP4-
inhibitor groups were prescribed for only three patients 
during the duration of  this study; this is likely because of  
the higher cost of  these drugs, their availability and potential 
safety issues. The cost of  drugs formed a substantial part 
(72.3%) of  the calculated direct costs in this study; this was 
higher than the 42.4% and 46% reported in studies from 
India and Pakistan42,43. The aggressive development and 
marketing of  generic medicines in these two Asian countries 
may account for the significantly lesser medication costs. 
Taking a cue from the Asian examples, it may be necessary 
for authorities in Nigeria to aggressively promote the use 
of  cheap and effective generic medicines to increase access 
and adherence to these medications. The mean cost of  
monthly medications of  about NGN N6556.60 (USD 
$39.70) found in this study indicates that a large chunk of  
the patients’ income is spent on drugs: over 70% of  the 
patients in this study earned less than NGN N50,000 (USD 
$303) monthly. This mismatch obviously has the potential to 
negatively impact patients’ medication adherence; however, 
the communal way of  life in Nigerian society means that the 
family usually supports or sponsors healthcare expenditures 
of  any ill member.
Using the MMAS-8, medication adherence was recorded as 
good (40.6%), moderate (32.8%), or poor (26.6%). Using the 
same study tool, Jamons et al. identified only 16.9% of  patients 
as poorly adherent in a study among 131 Palestinian diabetic 
patients, while Abebe et al. recorded 45.9%, 28.7% and 25.4% 
with high, medium and low adherence, respectively19,44. A 
Nigerian study using another tool, the Adherence and Self-
Management Monitoring Tool (ASMMT), found 59% of  
its sample diabetes patients to be non-adherent23. Ahmad 
et al. in a study among Malaysian diabetic patients found 
53% to be non-adherent using the Medication Compliance 
Questionnaire, while a study using pill count and other self-
reporting methods found adherence to be adequate in only 
29% of  patients20,45. The predictors of  medication non-
adherence shown in previous studies include disease and 
medication beliefs, poverty, service dissatisfaction, and using 
traditional medicines19,31,40,46,47. This study, in addition to 
some of  these aforementioned factors, identified inadequate 
information about the pharmacotherapy of  diabetes, high 
pill burden and non-availability of  prescribed drugs as 
obstacles to medication adherence among diabetes patients.
Conclusion
This study identified a satisfactory level of  adherence to 
diabetes medications in the population evaluated. There is 
a need for the integration of  generic medicines into routine 
care as a way of  further reducing the burden of  healthcare 
expenditure on the patients. The role or influence of  health-
care insurance on medical expenditure among diabetes pa-
tients in the Nigerian setting is a potential research topic for 
the future.
Study Limitations
The relatively small sample size and the fact that only one 
centre was used for the study were major limitations. This 
would mean that results of  the study might not be repre-
sentative of  other regions of  the country. Additionally, some 
respondents refused to disclose some sensitive information 
such as income level and age because of  fear about pos-
sible use of  their information for tax-related or other of-
ficial purposes. Though bias could arise from participant 
self-reporting and patients’ recall ability, the standardization 
and validation of  the data collection instruments used in the 
study act to mitigate such biases. Measuring adherence for 
all medications being taken by diabetes patients and not an-
tidiabetic agents alone may pose some questions. DM is a 
multi-system disease, however, with a myriad of  complica-
tions, and it therefore might not have been as practical to 
analyze only adherence to antidiabetic agents.
Acknowledgements
The authors are grateful to the entire staff  of  the medical 
outpatient department of  the Ladoke Akintola University 
of  Technology Teaching Hospital, Ogbomosho, Nigeria for 
their cooperation and support during the study period.
References
1. Mbanya JC, Motala AA, Sobngwi E, Assah FK, Enoru ST. Diabetes 
in sub-Saharan Africa. Lancet. 2010 Jun 26;375(9733):2254-66.
2. Ramachandran A, Snehalatha C. Current scenario of diabetes in 
India. J Diabetes. 2009 Mar;1(1):18-28.
3. Msyamboza KP, Mvula CJ, Kathyola D. Prevalence and correlates 
of diabetes mellitus in Malawi: population-based national NCD STEPS 
survey. BMC Endocr Disord. 2014;14:41.
4. Zimmet PZ, Magliano DJ, Herman WH, Shaw JE. Diabetes: a 
21st century challenge. The Lancet Diabetes & Endocrinology. 
2014;2(1):56-64.
5. Owoaje EE, Rotimi CN, Kaufman JS, Tracy J, Cooper RS. 
Prevalence of adult diabetes in Ibadan, Nigeria. East Afr Med J. 1997 
May;74(5):299-302.
6. Nyenwe EA, Odia OJ, Ihekwaba AE, Ojule A, Babatunde S. Type 2 
diabetes in adult Nigerians: a study of its prevalence and risk factors in 
Port Harcourt, Nigeria. Diabetes Res Clin Pract. 2003 Dec;62(3):177-
85.
7. Dahiru T, Jibo A, Hassan AA, Mande AT. Prevalence of diabetes in 
a semi-urban community in Northern Nigeria. Niger J Med. 2008 Oct-
Dec;17(4):414-6.
8. Alebiosu OC, Familoni OB, Ogunsemi OO, Raimi TH, Balogun WO, 
Odusan O, et al. Community based diabetes risk assessment in Ogun 
state, Nigeria (World Diabetes Foundation project 08-321). Indian J 
Endocrinol Metab. 2013 Jul;17(4):653-8.
9. Stratton IM, Adler AI, Neil HA, Matthews DR, Manley SE, Cull CA, 
et al. Association of glycaemia with macrovascular and microvascular 
complications of type 2 diabetes (UKPDS 35): prospective observational 
study. BMJ. 2000 Aug 12;321(7258):405-12.
10. Nathan DM, Cleary PA, Backlund JY, Genuth SM, Lachin JM, 
Orchard TJ, et al. Intensive diabetes treatment and cardiovascular 
disease in patients with type 1 diabetes. N Engl J Med. 2005 Dec 
22;353(25):2643-53.
11. Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA. 10-year 
follow-up of intensive glucose control in type 2 diabetes. N Engl J Med. 
2008 Oct 9;359(15):1577-89.
Malawi Medical Journal; 27 (2): 65-70 June 2015 Adherence and treatment costs DM in Nigeria  70
http://dx.doi.org/10.4314/mmj.v27i2.7
12. Boussageon R, Bejan-Angoulvant T, Saadatian-Elahi M, Lafont S, 
Bergeonneau C, Kassai B, et al. Effect of intensive glucose lowering 
treatment on all cause mortality, cardiovascular death, and microvascular 
events in type 2 diabetes: meta-analysis of randomised controlled trials. 
BMJ. 2011;343:d4169.
13. Yu AP, Yu YF, Nichol MB. Estimating the effect of medication 
adherence on health outcomes among patients with type 2 diabetes-
-an application of marginal structural models. Value Health. 2010 
Dec;13(8):1038-45.
14. DiBonaventura M, Wintfeld N, Huang J, Goren A. The association 
between nonadherence and glycated hemoglobin among type 2 
diabetes patients using basal insulin analogs. Patient Prefer Adherence. 
2014;8:873-82.
15. Breitscheidel L, Stamenitis S, Dippel FW, Schoffski O. Economic 
impact of compliance to treatment with antidiabetes medication in type 
2 diabetes mellitus: a review paper. J Med Econ. 2010 Mar;13(1):8-15.
16. Wild H. The economic rationale for adherence in the treatment of type 
2 diabetes mellitus. Am J Manag Care. 2012 Apr;18(3 Suppl):S43-8.
17. Benner JS, Chapman RH, Petrilla AA, Tang SS, Rosenberg N, 
Schwartz JS. Association between prescription burden and medication 
adherence in patients initiating antihypertensive and lipid-lowering 
therapy. Am J Health Syst Pharm. 2009 Aug 15;66(16):1471-7.
18. Farsaei S, Sabzghabaee AM, Zargarzadeh AH, Amini M. Adherence 
to glyburide and metformin and associated factors in type 2 diabetes in 
isfahan, iran. Iran J Pharm Res. 2011 Fall;10(4):933-9.
19. Abebe SM, Berhane Y, Worku A. Barriers to diabetes medication 
adherence in North West Ethiopia. Springerplus. 2014;3:195.
20. Ahmad NS, Ramli A, Islahudin F, Paraidathathu T. Medication 
adherence in patients with type 2 diabetes mellitus treated at primary 
health clinics in Malaysia. Patient Prefer Adherence. 2013;7:525-30.
21. Mukherjee S, Sharmasarkar B, Das KK, Bhattacharyya A, Deb 
A. Compliance to anti-diabetic drugs: observations from the diabetic 
clinic of a medical college in kolkata, India. J Clin Diagn Res. 2013 
Apr;7(4):661-5.
22. Pascal IG, Ofoedu JN, Uchenna NP, Nkwa AA, Uchamma GU. 
Blood Glucose Control and Medication Adherence Among Adult 
Type 2 Diabetic Nigerians Attending A Primary Care Clinic in Under-
resourced Environment of Eastern Nigeria. N Am J Med Sci. 2012 
Jul;4(7):310-5.
23. Yusuff KB, Obe O, Joseph BY. Adherence to anti-diabetic drug 
therapy and self management practices among type-2 diabetics in 
Nigeria. Pharm World Sci. 2008 Dec;30(6):876-83.
24. Adisa R, Fakeye TO. Effect of number and type of antidiabetes 
medications on adherence and glycemia of ambulatory type 2 diabetes 
patients in southwestern Nigeria. Pharm Pract (Granada). 2013 
Jul;11(3):156-65.
25. Rubin RR. Adherence to pharmacologic therapy in patients with 
type 2 diabetes mellitus. Am J Med. 2005 May;118 Suppl 5A:27S-34S.
26. Odeyemi IA, Nixon J. Assessing equity in health care through the 
national health insurance schemes of Nigeria and Ghana: a review-
based comparative analysis. Int J Equity Health. 2013;12:9.
27. Onoka CA, Hanson K, Hanefeld J. Towards universal coverage: a 
policy analysis of the development of the National Health Insurance 
Scheme in Nigeria. Health Policy Plan. 2014 Oct 21.
28. Onwujekwe O, Hanson K, Uzochukwu B. Examining inequities in 
incidence of catastrophic health expenditures on different healthcare 
services and health facilities in Nigeria. PLoS One. 2012;7(7):e40811.
29. Morisky DE, Ang A, Krousel-Wood M, Ward HJ. Predictive 
validity of a medication adherence measure in an outpatient setting. J 
Clin Hypertens (Greenwich). 2008 May;10(5):348-54.
30. Lee WY, Ahn J, Kim JH, Hong YP, Hong SK, Kim YT, et al. 
Reliability and validity of a self-reported measure of medication 
adherence in patients with type 2 diabetes mellitus in Korea. J Int Med 
Res. 2013 Aug;41(4):1098-110.
31. Al-Qazaz H, Sulaiman SA, Hassali MA, Shafie AA, Sundram S, Al-
Nuri R, et al. Diabetes knowledge, medication adherence and glycemic 
control among patients with type 2 diabetes. Int J Clin Pharm. 2011 
Dec;33(6):1028-35.
32. Ajayi EA, Adeoti AO, Ajayi IA, Ajayi AO, Adeyeye VO. Adherence 
to Antihypertensive Medications and Some of Its Clinical Implications 
in Patients Seen At a Tertiary Hospital in Nigeria.
33. Adewuya AO, Owoeye OA, Erinfolami AR, Coker AO, Ogun 
OC, Okewole AO, et al. Prevalence and correlates of poor medication 
adherence amongst psychiatric outpatients in southwestern Nigeria. 
Gen Hosp Psychiatry. 2009 Mar-Apr;31(2):167-74.
34. Adisa R, Fakeye TO, Fasanmade A. Medication adherence among 
ambulatory patients with type 2 diabetes in a tertiary healthcare setting 
in southwestern Nigeria. Pharm Pract (Granada). 2011 Apr;9(2):72-81.
35. Rhee MK, Slocum W, Ziemer DC, Culler SD, Cook CB, El-Kebbi 
IM, et al. Patient adherence improves glycemic control. Diabetes Educ. 
2005 Mar-Apr;31(2):240-50.
36. Sweileh WM, Zyoud SH, Abu Nab’a RJ, Deleq MI, Enaia MI, Nassar 
SM, et al. Influence of patients’ disease knowledge and beliefs about 
medicines on medication adherence: findings from a cross-sectional 
survey among patients with type 2 diabetes mellitus in Palestine. BMC 
Public Health. 2014;14:94.
37. Mafauzy M. Diabetes control and complications in public hospitals 
in Malaysia. Med J Malaysia. 2006 Oct;61(4):477-83.
38. Ahia CL, Holt EW, Krousel-Wood M. Diabetes care and its 
association with glycosylated hemoglobin level. Am J Med Sci. 2014 
Mar;347(3):245-7.
39. Shrestha SS, Shakya R, Karmacharya BM, Thapa P. Medication 
adherence to oral hypoglycemic agents among type II diabetic patients 
and their clinical outcomes with special reference to fasting blood 
glucose and glycosylated hemoglobin levels. Kathmandu Univ Med J 
(KUMJ). 2013 Jul-Sep;11(43):226-32.
40. Wabe NT, Angamo MT, Hussein S. Medication adherence in 
diabetes mellitus and self management practices among type-2 diabetics 
in Ethiopia. N Am J Med Sci. 2011 Sep;3(9):418-23.
41. Acharya KG, Shah KN, Solanki ND, Rana DA. Evaluation of 
antidiabetic prescriptions, cost and adherence to treatment guidelines: 
A prospective, cross-sectional study at a tertiary care teaching hospital. 
J Basic Clin Pharm. 2013 Sep;4(4):82-7.
42. Grover S, Avasthi A, Bhansali A, Chakrabarti S, Kulhara P. Cost of 
ambulatory care of diabetes mellitus: a study from north India. Postgrad 
Med J. 2005 Jun;81(956):391-5.
43. Khowaja LA, Khuwaja AK, Cosgrove P. Cost of diabetes care in out-
patient clinics of Karachi, Pakistan. BMC Health Serv Res. 2007;7:189.
44. Jamous RM, Sweileh WM, Abu-Taha AS, Sawalha AF, Zyoud 
SH, Morisky DE. Adherence and satisfaction with oral hypoglycemic 
medications: a pilot study in Palestine. Int J Clin Pharm. 2011 
Dec;33(6):942-8.
45. Mateo JF, Gil-Guillen VF, Mateo E, Orozco D, Carbayo JA, Merino 
J. Multifactorial approach and adherence to prescribed oral medications 
in patients with type 2 diabetes. Int J Clin Pract. 2006 Apr;60(4):422-8.
46. Mann DM, Ponieman D, Leventhal H, Halm EA. Predictors of 
adherence to diabetes medications: the role of disease and medication 
beliefs. J Behav Med. 2009 Jun;32(3):278-84.
47. Walz L, Pettersson B, Rosenqvist U, Deleskog A, Journath G, 
Wandell P. Impact of symptomatic hypoglycemia on medication 
adherence, patient satisfaction with treatment, and glycemic control in 
patients with type 2 diabetes. Patient Prefer Adherence. 2014;8:593-
601.
